Prime editing takes gene therapy to the next level

This study is led by Prof. Xianqun Fan (Department of Ophthalmology, Shanghai Jiao Tong University School of Medicine Affiliated Ninth People’s Hospital).

Risk adjusted net present value: What is the current valuation of Biomea Fusion’s Icovamenib?

Icovamenib is a small molecule commercialized by Biomea Fusion, with a leading Phase II program in Type 2 Diabetes.

November 20, 2023

Private Equity’s Tighter Grip; ApoB Inhibitors vs Liver? Promising New RDN System

Nearly half of all cardiology private practices were under private equity as of 2023, and there was a slight decrease in the proportion of groups

October 23, 2024

Opinion | Seeking Justice for Victims of the Opioid Epidemic

LaBelle is an expert in addiction policy and drug control law. With a 5-4 vote in Harrington v. Purdue Pharma, the U.S. Supreme Court rejected

June 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.